Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEF32D)

• Drug Name: TQ-1017 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMEF32D

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[3]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[4]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[5]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[6]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[7]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[6]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[8]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[9]

Drug(s) Targeting Opioid receptor mu (MOP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[10]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[11]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[12]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[7]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[13]
Alfentanil	DMVO0UB	Anaesthesia	9A78.6	Approved	[14]
Naloxegol	DML0B41	Opioid-induced constipation	DB32.1	Approved	[15]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[16]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[17]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[18]

Drug(s) Targeting 5-HT 2C receptor (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[19]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[20]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[21]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[22]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[23]
Methysergide	DM1EF73	Migraine	8A80	Approved	[24]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[25]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[26]
SR46349B	DM1ODMR	Primary insomnia	7A00	Phase 3	[27]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Agonist	[1]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Agonist	[1]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Agonist	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [3] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [4] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [5] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [6] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [7] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [8] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [9] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [10] Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
• [11] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [12] Clinical pipeline report, company report or official report of signaturerx.
• [13] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [14] Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
• [15] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [16] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [17] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [19] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [20] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [21] The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
• [22] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [23] Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
• [24] Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
• [25] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [26] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [27] SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
• [28] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.